nach oben

Erschienen in:

01.10.2019 | Commentary

Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017”

verfasst von: Agnieszka Pozdzik, Naim Maalouf, Emmanuel Letavernier, Isabelle Brocheriou, Jean-Jacques Body, Benjamin Vervaet, Carl Van Haute, Johanna Noels, Romy Gadisseur, Vincent Castiglione, Frédéric Cotton, Giovanni Gambaro, Michel Daudon, Khashayar Sakhaee

Erschienen in: Journal of Nephrology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

A symposium on kidney stones and mineral metabolism held on December 2017 in Brussels, Belgium was the first international multidisciplinary conference of the International Collaborative Network on Kidney Stones and Mineral Metabolism. This meeting addressed epidemiology, underlying pathophysiological mechanisms, genetics, pathological, as well as clinical and research topics. The participants included clinicians and recognized experts in the field from Europe and the United States interacted closely during the symposium which promoted a chance to explore new frontiers in the field of kidney stone disease. This manuscript summarizes some of the major highlights of the meeting.

Sakhaee K, Maalouf NM, Sinnott B (2012) Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97(6):1847–1860CrossRefPubMedPubMedCentral

Romero V, Akpinar H, Assimos DG (2010) Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 12(2–3):e86–e96PubMedPubMedCentral

Shuster J, Scheaffer RL (1984) Economic impact of kidney stones in white male adults. Urology 24(4):327–331CrossRefPubMed

Cone EB, Hammill BG, Routh JC, Lipkin ME, Preminger GM, Schmader KE et al (2018) Disproportionate use of inpatient care by older adults with kidney stones. Urology 120:103–108CrossRefPubMedPubMedCentral

Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America P (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165CrossRefPubMedPubMedCentral

Zeng G, Mai Z, Xia S, Wang Z, Zhang K, Wang L et al (2017) Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int 120(1):109–116CrossRefPubMed

Ramello A, Vitale C, Marangella M (2000) Epidemiology of nephrolithiasis. J Nephrol 13(Suppl 3):S45–S50PubMed

Xu LHR, Adams-Huet B, Poindexter JR, Maalouf NM, Moe OW, Sakhaee K (2017) Temporal changes in kidney stone composition and in risk factors predisposing to stone formation. J Urol 197(6):1465–1471CrossRefPubMedPubMedCentral

Shavit L, Ferraro PM, Johri N, Robertson W, Walsh SB, Moochhala S et al (2015) Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol Dial Transpl 30(4):607–613CrossRef

10.

Daudon M (2005) [Epidemiology of nephrolithiasis in France]. Ann Urol (Paris) 39(6):209–231CrossRef

11.

Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G (2003) Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol 169(6):2026–2029CrossRefPubMed

12.

Daudon M, Donsimoni R, Hennequin C, Fellahi S, Le Moel G, Paris M et al (1995) Sex- and age-related composition of 10 617 calculi analyzed by infrared spectroscopy. Urol Res 23(5):319–326CrossRefPubMed

13.

Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4(4):804–811CrossRefPubMedPubMedCentral

14.

Maeda S, Naganuma T, Takemoto Y, Shoji T, Okamura M, Nakatani T (2012) Chronic kidney disease in urolithiasis patients following successful extracorporeal shockwave lithotripsy. Mol Med Rep 5(1):3–6PubMed

15.

Shang W, Li L, Ren Y, Ge Q, Ku M, Ge S et al (2017) History of kidney stones and risk of chronic kidney disease: a meta-analysis. PeerJ 5:e2907CrossRefPubMedPubMedCentral

16.

Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6(8):2069–2075CrossRefPubMedPubMedCentral

17.

Goldfarb DS, Fischer ME, Keich Y, Goldberg J (2005) A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 67(3):1053–1061CrossRefPubMed

18.

Gambaro G, Vezzoli G, Casari G, Rampoldi L, D’Angelo A, Borghi L (2004) Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 44(6):963–986CrossRefPubMed

19.

Edvardsson VO, Palsson R, Indridason OS, Thorvaldsson S, Stefansson K (2009) Familiality of kidney stone disease in Iceland. Scand J Urol Nephrol 43(5):420–424CrossRefPubMed

20.

Guerra A, Folesani G, Nouvenne A, Ticinesi A, Allegri F, Pinelli S et al (2016) Family history influences clinical course of idiopathic calcium nephrolithiasis: case-control study of a large cohort of Italian patients. J Nephrol 29(5):645–651CrossRefPubMed

21.

Toka HR, Genovese G, Mount DB, Pollak MR, Curhan GC (2013) Frequency of rare allelic variation in candidate genes among individuals with low and high urinary calcium excretion. PLoS One 8(8):e71885CrossRefPubMedPubMedCentral

22.

Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF et al (2009) Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41(8):926–930CrossRefPubMed

23.

Yasui T, Okada A, Urabe Y, Usami M, Mizuno K, Kubota Y et al (2013) A replication study for three nephrolithiasis loci at 5q35.3, 7p14.3 and 13q14.1 in the Japanese population. J Hum Genet 58(9):588–593CrossRefPubMed

24.

Oliveira B, Kleta R, Bockenhauer D, Walsh SB (2016) Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. Am J Physiol Renal Physiol 311(6):F1243–F1252CrossRefPubMed

25.

Shavit L, Jaeger P, Unwin RJ (2015) What is nephrocalcinosis? Kidney Int 88(1):35–43CrossRefPubMed

26.

Michalus I, Rusinska A (2018) Rare, genetically conditioned forms of rickets: Differential diagnosis and advances in diagnostics and treatment. Clin Genet 94(1):103–114CrossRefPubMed

27.

Sayer JA, Carr G, Simmons NL (2004) Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. Clin Sci (Lond) 106(6):549–561CrossRef

28.

Taguchi K, Yasui T, Milliner DS, Hoppe B, Chi T (2017) Genetic risk factors for idiopathic urolithiasis: a systematic review of the literature and causal network analysis. Eur Urol Focus 3(1):72–81CrossRefPubMed

29.

Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS et al (2015) Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26(3):543–551CrossRefPubMed

30.

Braun DA, Lawson JA, Gee HY, Halbritter J, Shril S, Tan W et al (2016) Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol 11(4):664–672CrossRefPubMedPubMedCentral

31.

Daga A, Majmundar AJ, Braun DA, Gee HY, Lawson JA, Shril S et al (2018) Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int 93(1):204–213CrossRefPubMed

32.

Pelle A, Cuccurullo A, Mancini C, Sebastiano R, Stallone G, Negrisolo S et al (2017) Updated genetic testing of Italian patients referred with a clinical diagnosis of primary hyperoxaluria. J Nephrol 30(2):219–225CrossRefPubMed

33.

Diefenhardt P, Nosko A, Kluger MA, Richter JV, Wegscheid C, Kobayashi Y et al (2018) IL-10 receptor signaling empowers regulatory T cells to control Th17 responses and protect from GN. J Am Soc Nephrol 29(7):1825–1837CrossRefPubMedPubMedCentral

34.

Cloutier J, Villa L, Traxer O, Daudon M (2015) Kidney stone analysis: “Give me your stone, I will tell you who you are!”. World J Urol 33(2):157–169CrossRefPubMed

35.

Siener R, Buchholz N, Daudon M, Hess B, Knoll T, Osther PJ et al (2016) Quality assessment of urinary stone analysis: results of a multicenter study of laboratories in Europe. PLoS One 11(6):e0156606CrossRefPubMedPubMedCentral

36.

Daudon M, Dessombz A, Frochot V, Letavernier E, Haymann JP, Jungers P, Bazin D (2016) Comprehensive morpho-constitutional analysis of urinary stones improves etiological diagnosis and therapeutic strategy of nephrlithiasis. C R Chim 19:1470–1491CrossRef

37.

Reveillaud RJ, Daudon M, Protat MF, Ayrole G (1980) Analysis of urinary calculi in adults. Attempt of correlations between morphology and composition. Eur Urol 6(3):161–165CrossRefPubMed

38.

Daudon M, Estepa L, Lacour B, Jungers P (1998) Unusual morphology of calcium oxalate calculi in primary hyperoxaluria. J Nephrol 11(Suppl 1):51–55PubMed

39.

Sakhaee K, Maalouf NM (2008) Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 28(2):174–180CrossRefPubMed

40.

Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K (2007) Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol 2(5):883–888CrossRefPubMed

41.

Moe OW, Xu LHR (2018) Hyperuricosuric calcium urolithiasis. J Nephrol 31(2):189–196CrossRefPubMed

42.

Goldfarb DS, Hirsch J. Hypothesis (2015) Urbanization and exposure to urban heat islands contribute to increasing prevalence of kidney stones. Med Hypotheses 85(6):953–957CrossRefPubMedPubMedCentral

43.

Ferraro PM, Curhan GC, D’Addessi A, Gambaro G (2017) Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol 30(2):227–233CrossRefPubMed

44.

Vervaet BA, Verhulst A, D’Haese PC, De Broe ME (2009) Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transpl 24(7):2030–2035CrossRef

45.

Vervaet BA, D’Haese PC, De Broe ME, Verhulst A (2009) Crystalluric and tubular epithelial parameters during the onset of intratubular nephrocalcinosis: illustration of the ‘fixed particle’ theory in vivo. Nephrol Dial Transpl 24(12):3659–3668CrossRef

46.

Vervaet BA, Verhulst A, De Broe ME, D’Haese PC (2010) The tubular epithelium in the initiation and course of intratubular nephrocalcinosis. Urol Res 38(4):249–256CrossRefPubMed

47.

Verhulst A, Asselman M, De Naeyer S, Vervaet BA, Mengel M, Gwinner W et al (2005) Preconditioning of the distal tubular epithelium of the human kidney precedes nephrocalcinosis. Kidney Int 68(4):1643–1647CrossRefPubMed

48.

Letavernier E, Vandermeersch S, Traxer O, Tligui M, Baud L, Ronco P et al (2015) Demographics and characterization of 10,282 Randall plaque-related kidney stones: a new epidemic? Medicine (Baltimore) 94(10):e566CrossRef

49.

Verrier C, Bazin D, Huguet L, Stephan O, Gloter A, Verpont MC et al (2016) Topography, composition and structure of incipient randall plaque at the nanoscale level. J Urol 196(5):1566–1574CrossRefPubMed

50.

Letavernier E, Daudon M (2018) Vitamin D, Hypercalciuria and kidney stones. Nutrients 10(3):366CrossRefPubMedCentral

51.

Letavernier E, Daudon M. Stones (2016) Tolvaptan might prevent kidney stone formation. Nat Rev Urol 13(3):130–131CrossRefPubMed

52.

Letavernier E, Kauffenstein G, Huguet L, Navasiolava N, Bouderlique E, Tang E et al (2018) ABCC6 deficiency promotes development of randall plaque. J Am Soc Nephrol 29:2337–2347CrossRef

53.

Kumakura S, Nakaya I, Sakuma T, Sato H, Soma J (2016) Crystalline cast nephropathy in a patient with IgD lambda myeloma. Clin Exp Nephrol 20(3):491–492CrossRefPubMed

54.

Gupta V, El Ters M, Kashani K, Leung N, Nasr SH (2015) Crystalglobulin-induced nephropathy. J Am Soc Nephrol 26(3):525–529CrossRefPubMed

55.

Chatchen S, Pongsakul N, Srisomsap C, Chiangjong W, Hongeng S, Svasti J et al (2018) Unravelling pathophysiology of crystalline nephropathy in ceftriaxone-associated acute kidney injury: a cellular proteomic approach. Nephron 139(1):70–82CrossRefPubMed

56.

Carbone LG, Bendixen B, Appel GB (1988) Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis 12(1):72–75CrossRefPubMed

57.

Sawyer MH, Webb DE, Balow JE, Straus SE (1988) Acyclovir-induced renal failure. Clinical course and histology. Am J Med 84(6):1067–1071CrossRefPubMed

58.

Nasr SH, Milliner DS, Wooldridge TD, Sethi S (2014) Triamterene crystalline nephropathy. Am J Kidney Dis 63(1):148–152CrossRefPubMed

59.

Santoriello D, Al-Nabulsi M, Reddy A, Salamera J, D’Agati VD, Markowitz GS (2017) Atazanavir-associated crystalline nephropathy. Am J Kidney Dis 70(4):576–580CrossRefPubMed

60.

Daudon M, Frochot V, Bazin D, Jungers P (2018) Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs 78(2):163–201CrossRefPubMed

61.

Cartery C, Faguer S, Karras A, Cointault O, Buscail L, Modesto A et al (2011) Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol 6(8):1895–1902CrossRefPubMedPubMedCentral

62.

Chuang YW, Wen MC, Wu MJ, Shu KH, Cheng CH, Yu TM et al (2012) Follow-up and treatment of renal transplantation with nephropathic cystinosis in central Taiwan. Transpl Proc 44(1):80–82CrossRef

63.

Ceballos-Picot I, Perignon JL, Hamet M, Daudon M, Kamoun P (1992) 2,8-Dihydroxyadenine urolithiasis, an underdiagnosed disease. Lancet 339(8800):1050–1051CrossRefPubMed

64.

Bollee G, Cochat P, Daudon M (2015) Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health Dis 2:31CrossRefPubMedPubMedCentral

65.

Fogazzi GB (1996) Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transpl 11(2):379–387CrossRef

66.

Daudon M, Frochot V (2015) Crystalluria. Clin Chem Lab Med 53(Suppl 2):s1479–87PubMed

67.

Scales CD Jr, Tasian GE, Schwaderer AL, Goldfarb DS, Star RA, Kirkali Z (2016) Urinary stone disease: advancing knowledge, patient care, and population health. Clin J Am Soc Nephrol 11(7):1305–1312CrossRefPubMedPubMedCentral

68.

Tasian GE, Ross ME, Song L, Sas DJ, Keren R, Denburg MR et al (2016) Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin J Am Soc Nephrol 11(3):488–496CrossRefPubMedPubMedCentral

69.

Jungers P, Joly D, Barbey F, Choukroun G, Daudon M (2004) ESKD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 44(5):799–805CrossRefPubMed

70.

Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S et al (2012) Kidney stones and kidney function loss: a cohort study. BMJ 345:e5287CrossRefPubMedPubMedCentral

71.

Denburg MR, Jemielita TO, Tasian GE, Haynes K, Mucksavage P, Shults J et al (2016) Assessing the risk of incident hypertension and chronic kidney disease after exposure to shock wave lithotripsy and ureteroscopy. Kidney Int 89(1):185–192CrossRefPubMedPubMedCentral

72.

El-Zoghby ZM, Lieske JC, Foley RN, Bergstralh EJ, Li X, Melton LJ 3rd et al (2012) Urolithiasis and the risk of ESKD. Clin J Am Soc Nephrol 7(9):1409–1415CrossRefPubMedPubMedCentral

73.

Gambaro G, Croppi E, Bushinsky D, Jaeger P, Cupisti A, Ticinesi A et al (2017) The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review. J Urol 198(2):268–273CrossRefPubMed

74.

Spatola L, Angelini C, Badalamenti S, Maringhini S, Gambaro G (2017) Kidney stones diseases and glycaemic statuses: focus on the latest clinical evidences. Urolithiasis 45(5):457–460CrossRefPubMed

75.

Worcester EM, Parks JH, Evan AP, Coe FL (2006) Renal function in patients with nephrolithiasis. J Urol 176(2):600–603 (discussion 3) CrossRefPubMed

76.

Connors BA, Evan AP, Willis LR, Blomgren PM, Lingeman JE, Fineberg NS (2000) The effect of discharge voltage on renal injury and impairment caused by lithotripsy in the pig. J Am Soc Nephrol 11(2):310–318PubMed

77.

Petrucci I, Clementi A, Sessa C, Torrisi I, Meola M (2018) Ultrasound and color Doppler applications in chronic kidney disease. J Nephrol 31(6):863–879CrossRefPubMed

78.

Zerwekh JE, Hwang TI, Poindexter J, Hill K, Wendell G, Pak CY (1988) Modulation by calcium of the inhibitor activity of naturally occurring urinary inhibitors. Kidney Int 33(5):1005–1008CrossRefPubMed

79.

Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139(4):679–684CrossRefPubMed

80.

Norman DA, Zerwekh JE, Pak CY (1981) An apparent 1,25-dihydroxyvitamin D-independent stimulation of intestinal calcium absorption in patients with Paget disease of bone during a short-term diphosphonate therapy. Metabolism 30(3):290–292CrossRefPubMed

81.

Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y et al (2012) Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 97(3):E423–E427CrossRefPubMedPubMedCentral

82.

Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM et al (2008) Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 19(6):1197–1203CrossRefPubMedPubMedCentral

83.

Ricagno S, Jonsson S, Richards N, Lindqvist Y (2003) Formyl-CoA transferase encloses the CoA binding site at the interface of an interlocked dimer. EMBO J 22(13):3210–3219CrossRefPubMedPubMedCentral

84.

Siener R, Bangen U, Sidhu H, Honow R, von Unruh G, Hesse A (2013) The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int 83(6):1144–1149CrossRefPubMed

85.

Maalouf NM, Moe OW, Adams-Huet B, Sakhaee K (2011) Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab 96(12):3733–3740CrossRefPubMedPubMedCentral

86.

Ticinesi A, Guerra A, Allegri F, Nouvenne A, Cervellin G, Maggio M et al (2018) Determinants of calcium and oxalate excretion in subjects with calcium nephrolithiasis: the role of metabolic syndrome traits. J Nephrol 31(3):395–403CrossRefPubMed

87.

Adami S, Marcocci C, Gatti D (2002) Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 17(Suppl 2):N18–N23PubMed

88.

Bilezikian JP, Silverberg SJ (2004) Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 350(17):1746–1751CrossRefPubMed

89.

Lal G, Clark OH (2003) Primary hyperparathyroidism: controversies in surgical management. Trends Endocrinol Metab 14(9):417–422CrossRefPubMed

90.

Bilezikian JP, Potts JT Jr, Fuleihan Gel H, Kleerekoper M, Neer R, Peacock M et al (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87(12):5353–5361CrossRefPubMed

91.

Bilezikian JP, Potts JT Jr (2002) Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future. J Bone Miner Res 17(Suppl 2):N57–N67PubMed

92.

Ruda JM, Hollenbeak CS, Stack BC Jr (2005) Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 132(3):359–372CrossRefPubMed

93.

Daudon M, Lacour B, Jungers P (2006) Influence of body size on urinary stone composition in men and women. Urol Res 34(3):193–199CrossRefPubMed

94.

Sakhaee K (2008) Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 17(3):304–309CrossRefPubMed

95.

Sakhaee K (2014) Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol 27(3):241–245CrossRefPubMedPubMedCentral

96.

Maalouf NM, Cameron MA, Moe OW, Sakhaee K (2010) Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol 5(7):1277–1281CrossRefPubMedPubMedCentral

97.

Daudon M, Traxer O, Conort P, Lacour B, Jungers P (2006) Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 17(7):2026–2033CrossRefPubMed

98.

Fernandez A, Fuller A, Al-Bareeq R, Nott L, Razvi H (2013) A comparison of the metabolic profiles of diabetic and non-diabetic uric acid stone formers. Can Urol Assoc J 7(3–4):E190–E192CrossRefPubMedPubMedCentral

99.

Nikiforova VJ, Giesbertz P, Wiemer J, Bethan B, Looser R, Liebenberg V et al (2014) Glyoxylate, a new marker metabolite of type 2 diabetes. J Diabetes Res 2014:685204CrossRefPubMedPubMedCentral

100.

Burdin DV, Kolobov AA, Brocker C, Soshnev AA, Samusik N, Demyanov AV et al (2016) Diabetes-linked transcription factor HNF4alpha regulates metabolism of endogenous methylarginines and beta-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2. Sci Rep 6:35503CrossRefPubMedPubMedCentral

101.

Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ (1997) Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126(7):497–504CrossRefPubMed

102.

Sakhaee K, Poindexter JR, Griffith CS, Pak CY (2004) Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. J Urol 172(3):958–961CrossRefPubMed

103.

Karp HJ, Ketola ME, Lamberg-Allardt CJ (2009) Acute effects of calcium carbonate, calcium citrate and potassium citrate on markers of calcium and bone metabolism in young women. Br J Nutr 102(9):1341–1347CrossRefPubMed

104.

Green JH, Booth C, Bunning R (2003) Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption. Eur J Clin Nutr 57(1):61–68CrossRefPubMed

105.

Ketha H, Singh RJ, Grebe SK, Bergstralh EJ, Rule AD, Lieske JC et al (2015) Altered calcium and vitamin D homeostasis in first-time calcium kidney stone-formers. PLoS One 10(9):e0137350CrossRefPubMedPubMedCentral

106.

Hu H, Zhang J, Lu Y, Zhang Z, Qin B, Gao H et al. Association between circulating vitamin D Level and urolithiasis: a systematic review and meta-analysis. Nutrients. 2017;9(3):301CrossRefPubMedCentral

107.

Bambach CP, Robertson WG, Peacock M, Hill GL (1981) Effect of intestinal surgery on the risk of urinary stone formation. Gut 22(4):257–263CrossRefPubMedPubMedCentral

108.

Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ et al (2011) Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery 149(5):654–661CrossRefPubMedPubMedCentral

109.

Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG (2015) Kidney stones are common after bariatric surgery. Kidney Int 87(4):839–845CrossRefPubMed

110.

Canales BK, Hatch M (2014) Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies. Surg Obes Relat Dis 10(4):734–742CrossRefPubMedPubMedCentral

111.

Pareek G, Armenakas NA, Panagopoulos G, Bruno JJ, Fracchia JA (2005) Extracorporeal shock wave lithotripsy success based on body mass index and Hounsfield units. Urology 65(1):33–36CrossRefPubMed

112.

Castiglione V, Jouret F, Bruyere O, Dubois B, Thomas A, Waltregny D et al (2015) [Epidemiology of urolithiasis in Belgium on the basis of a morpho-constitutional classification]. Nephrol Ther 11(1):42–49CrossRefPubMed

113.

Sakhaee K (2017) Medical measures for secondary prevention of urolithiasis. Eur Urol Focus 3(1):10–12CrossRefPubMedPubMedCentral

114.

Sakhaee K, Harvey JA, Padalino PK, Whitson P, Pak CY (1993) The potential role of salt abuse on the risk for kidney stone formation. J Urol 150(2 Pt 1):310–312CrossRefPubMed

115.

Sakhaee K, Williams RH, Oh MS, Padalino P, Adams-Huet B, Whitson P et al (1993) Alkali absorption and citrate excretion in calcium nephrolithiasis. J Bone Miner Res 8(7):789–794CrossRefPubMed

116.

Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E et al (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29(6):715–734CrossRefPubMedPubMedCentral

Titel: Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017”
verfasst von: Agnieszka Pozdzik
Naim Maalouf
Emmanuel Letavernier
Isabelle Brocheriou
Jean-Jacques Body
Benjamin Vervaet
Carl Van Haute
Johanna Noels
Romy Gadisseur
Vincent Castiglione
Frédéric Cotton
Giovanni Gambaro
Michel Daudon
Khashayar Sakhaee
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 5/2019
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-019-00587-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017”

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Updates on urinary tract infections in kidney transplantation

When kidneys and lungs suffer together

Role of anemia and proteinuria in the development of subsequent renal function deterioration in a general population with preserved glomerular filtration rate: a community-based cohort study

Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis

Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis

The role of the intestinal microbiota in uremic solute accumulation: a focus on sulfur compounds

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin